程客铭　文跃强　胡静　颜家渝　赵永红

【摘要】 目的：应用中医传承辅助平台分析中医药治疗支气管哮喘方剂的组方用药规律。方法：筛选中国期刊全文数据库（CNKI）、维普期刊资源整合服务平台（VIP）及万方数据知识服务平台（Wanfang）中治疗支气管哮喘的方剂，通过中医传承辅助平台（V2.5）构建方剂信息数据库，利用该平台的关联规则及熵聚类等数据挖掘算法，分析治疗支气管哮喘方剂中的常用药对、组方规则、潜在药对及发现新方。结果：通过对153首抗支气管哮喘方剂所含药物的频次统计分析，得出抗支气管哮喘的常用药物有44味，而使用频次较高的药对有44个，通过熵层次聚类分析算法发现关联系数较高的潜在药对20个及潜在新方10个。结论：CNKI、VIP和Wanfang中收录治疗支气管哮喘的方剂配伍多以宣肺止咳化痰、降气平喘、祛风清热类药物为主，挖掘得到的新方具有潜在的临床应用和新药开发价值。

【关键词】 中医传承辅助平台； 支气管哮喘； 方剂； 组方用药规律

【Abstract】 Objective：To apply traditional Chinese medicine inheritance support system to analyze the prescription drugs of traditional Chinese medicine treating bronchial asthma prescription.Method：The China journal full-text database（CNKI），VIP journals resource integration service platform （VIP） and the data knowledge service platform of Wanfang（Wanfang） in the treatment of bronchial asthma were Screened，through the traditional Chinese medicine inheritance （V2.5） build proprietary information database，the association rules of the platform and entropy clustering data mining algorithms were given，such as analysis of treating bronchial asthma with commonly used medicines in prescriptions for potential drugs，sets of rules，and found New Prescription.Result：Based on the analysis of 153 cases of prescriptions，the frequency of each herb and association rules among herbs included in the database are computed，44 core combinations，20 potential drug pairs and 10 new prescriptions were mined from the database.Conclusion：CNKI，VIP and Wanfang that include the prescription for the treatment of bronchial asthma are mainly used to promote phlegm， reduce asthma， and dispel wind and heat， mining of New prescription has a potential value of clinical application and new drugs development.

【Key words】 Traditional Chinese medicine inheritance support system； Bronchial asthma； Prescription； Principle of prescription

First-authors address：Guangan Traditional Chinese Medicine Hospital，Guangan 638600，China

doi：10.3969/j.issn.1674-4985.2018.22.038

支氣管哮喘（bronchial asthma）是一种以嗜酸细胞、肥大细胞为主的气道变应原性慢性炎症性疾病，以慢性气道炎症、气道高反应性和气道重塑为主要特征，与遗传和环境因素有关[1-3]。根据最新全球哮喘防治创议“（GINA方案）”数据统计，当前全球约3亿哮喘患者，到2025年全球将新增约

1亿患者，该病已成为当今世界威胁公共健康最常见的慢性肺部疾病[4-6]。我国是哮喘高发病国家，约有2 000万例哮喘患者，患者低龄化趋势明显，发病率呈现逐年上升趋势[7]。……